Neuren Pharmaceuticals Limited

ASX (AUD): Neuren Pharmaceuticals Limited (NEU)

Last Price

12.43

Today's Change

-1.26 (9.20%)

Day's Change

12.42 - 13.68

Trading Volume

1,147,833

Overview

Market Cap

1 Billion

Shares Outstanding

127 Million

Avg Volume

543,661

Avg Price (50 Days)

13.90

Avg Price (200 Days)

17.95

PE Ratio

12.81

EPS

0.97

Earnings Announcement

29-Jan-2025

Previous Close

13.69

Open

13.58

Day's Range

12.42 - 13.68

Year Range

12.02 - 25.95

Trading Volume

1,147,833

Price Change Highlight

1 Day Change

-9.20%

5 Day Change

-28.97%

1 Month Change

-3.72%

3 Month Change

-19.70%

6 Month Change

-40.04%

Ytd Change

-49.92%

1 Year Change

-17.95%

3 Year Change

575.54%

5 Year Change

401.21%

10 Year Change

440.43%

Max Change

117.69%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment